Related Experiment Videos
Colchicine for primary biliary cirrhosis.
1Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Dept. 7102, Blegdamsvej 9, H:S Rigshospitalet, Copenhagen, Denmark, DK-2100.
The Cochrane Database of Systematic Reviews
|April 24, 2004
Summary
Colchicine shows inconsistent therapeutic responses in primary biliary cirrhosis patients. This review found no evidence to support or refute its use, suggesting it should only be administered within clinical trials.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Colchicine, known for immunomodulatory and antifibrotic properties, has been explored for primary biliary cirrhosis (PBC).
- Previous randomized clinical trials (RCTs) yielded inconsistent therapeutic responses.
Purpose of the Study:
- To systematically evaluate the beneficial and harmful effects of colchicine in patients diagnosed with primary biliary cirrhosis.
Main Methods:
- Conducted comprehensive electronic and manual searches for RCTs comparing colchicine with control therapies.
- Included 11 RCTs with 716 PBC patients, analyzing outcomes like mortality, liver complications, and adverse events using fixed and random effects models.
Main Results:
- Colchicine did not significantly impact mortality, liver transplantation rates, complications, biochemical variables, or histological measurements compared to placebo.
- A significant decrease in patients without pruritus improvement was observed, though based on limited data.
- Sensitivity analyses indicated potential detrimental effects on mortality in worst-case scenarios.
Conclusions:
- Current evidence does not support or refute the use of colchicine for primary biliary cirrhosis.
- Given the potential for adverse effects, colchicine use should be restricted to randomized clinical trials for PBC patients.